alanine has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 6.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| "Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR)." | 2.84 | A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. ( Aghajanian, C; Bonebrake, AJ; Chafe, W; Chan, JK; Deng, W; Gaillard, S; Hicks, M; Higgins, RV; Monk, BJ; Ramirez, PT; Tewari, KS, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, JK | 1 |
| Deng, W | 1 |
| Higgins, RV | 1 |
| Tewari, KS | 1 |
| Bonebrake, AJ | 1 |
| Hicks, M | 1 |
| Gaillard, S | 1 |
| Ramirez, PT | 1 |
| Chafe, W | 1 |
| Monk, BJ | 1 |
| Aghajanian, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)[NCT01267253] | Phase 2 | 31 participants (Actual) | Interventional | 2011-04-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1 (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicated based on symptoms or physical signs suggestive of progressive disease.
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.071 |
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.. (NCT01267253)
Timeframe: From study entry to time of death or the date of last contact, up to 5 years of follow-up.
| Intervention | Months (Median) |
|---|---|
| Brivanib | 7.9 |
Proportion of participants who survive progression-free for at least 6 months without non-protocol therapy from study entry. Progression is assessed by RECIST 1.1. (NCT01267253)
Timeframe: Every other cycle for first 6 months; then every 3 months therafter until disease progression confirmed; and at any other time if cliniclly indicated based on symptoms or physical signs suggestive of progressive disease
| Intervention | proportion (Number) |
|---|---|
| Brivanib | 0.179 |
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1 (NCT01267253)
Timeframe: From study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up
| Intervention | Months (Median) |
|---|---|
| Brivanib | 3.2 |
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v.4.0 (NCT01267253)
Timeframe: During treatment period and up to 30 days after stopping the study treatment.
| Intervention | Participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukopenia | Thrombocytopenia | Neutropenia | Anemia | Other Investigations | Cardiac Disorders | Gastrointestinal Disorders | General disorders & administration site conditions | Hepatobiliary Disorders | Infections and infestations | Metabolism and nutrition disorders | Musculoskeletal & connective tissue disorders | Neoplasms benign, malignant & unspecified | Nervous system disorders | Renal and urinary disorders | Vascular Disorders | |
| Brivanib | 0 | 0 | 0 | 4 | 4 | 1 | 7 | 2 | 1 | 4 | 5 | 3 | 2 | 3 | 2 | 5 |
1 trial available for alanine and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma; Disease Progression; Dise | 2017 |